Program
arumakimig
Also written as “MAS825” and “Arumakimig”.
In Novartis's pipeline, IL18 Inhibitor, IL1B
. Its studies are mostly in Arthritis, Juvenile · Arthritis · Hidradenitis Suppurativa · Enterocolitis · Coronary Disease, led by Novartis.
Furthest: phase 2, since Jan 31, 20197 company-led studies, 3 open or runningNext primary completion: Apr 22, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 73 open or running | phase 2since Jan 31, 2019 | Jan 31, 2019 | Apr 22, 2027phase 2 · NCT07203001 |
- Named in Novartis’s own pipeline as
MAS825 (arumakimig)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2019First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT03827798 · 248 enrolled · United States, Austria, Belgium and more
- May 8, 2020Phase 2 study in Respiratory InsufficiencyNCT04382651 · 140 enrolled · United States
- Nov 20, 2020Phase 2 study in Lymphoproliferative Syndrome, X-Linked, 2NCT04641442 · 17 enrolled · United States, Czechia, France and more
- Nov 30, 2020Phase 1 study in Healthy VolunteersNCT04665154 · 80 enrolled · United States, United Kingdom
- Oct 18, 2023Phase 2 study in Coronary DiseaseNCT06097663 · 31 enrolled · United States, Canada, Germany
- Sep 9, 2025Phase 2 study in Arthritis, JuvenileNCT07203001 · 30 planned · United States, Canada, France and more
- Jul 31, 2026Phase 2 study in VEXAS syndromeNCT07748624 · 120 planned · Japan
Ahead
- Apr 22, 2027Primary completion: phase 2 study in Arthritis, JuvenileNCT07203001
- Dec 26, 2028Primary completion: phase 2 study in VEXAS syndromeNCT07748624
TargetBeta
“IL18 Inhibitor, IL1B”the company's pipeline, read by Claude · source
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07748624VEXAS syndrome · Japan | 2 | Recruiting | Dec 26, 2028 | 120 |
| NCT07203001Arthritis, Juvenile · United States, Canada, France and more | 2 | Recruiting | Apr 22, 2027 | 30 |
| NCT06097663Coronary Disease · United States, Canada, Germany | 2 | Completed | Oct 27, 2024 | 31 |
| NCT04665154Healthy Volunteers · United States, United Kingdom | 1 | Completed | Aug 3, 2022 | 80 |
| NCT04641442Lymphoproliferative Syndrome, X-Linked, 2 · United States, Czechia, France and more | 2 | Active, not recruiting | Oct 14, 2025 | 17 |
| NCT04382651Respiratory Insufficiency · United States | 2 | Completed | Jan 6, 2021 | 140 |
| NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more | 2 | Completed | Dec 4, 2024 | 248 |
How it is read
Names in the registry
- “MAS825”, 6 entries
- “Arumakimig”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Juvenile, 1 study
- Arthritis, 1 study
- Hidradenitis Suppurativa, 1 study
- Enterocolitis, 1 study
- Coronary Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.